Research
Hormonal
Ghrelin is the only known orexigenic gut hormone, and its levels are inversely correlated with body mass index, with obese subjects showing a less marked drop in plasma ghrelin after meal ingestion.
Ghrelin is the 'hunger hormone,' and its levels are lower in obese individuals. However, obese people have a blunted response to meals, meaning their ghrelin doesn't drop as much as it should, potentially contributing to overeating.
GoodSupportsHIGH confidence
Ghrelin... is the only known orexigenic gut hormone... Negative correlations between circulating ghrelin levels and body mass index are found in human. In contrast, obese subjects show a less marked drop in plasma ghrelin after meal ingestion
Why this rating
The paper cites multiple studies showing the inverse correlation and the blunted response in obesity.
Source
Obesity and Appetite Control
Keisuke Suzuki et al. · Experimental Diabetes Research · 2012
DOI 10.1155/2012/824305
narrative_reviewCited 226×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Peripheral administration of PYY3-36 reduces food intake and body weight gain in both lean and obese human subjects by acting on hypothalamic Y2 receptors, with sensitivity preserved in obesity unlike leptin.Good
- GLP-1 receptor agonists (e.g., exenatide, liraglutide) reduce food intake and body weight in humans, but their use is limited by side effects like nausea and potential long-term risks.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →